Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Unconventional Control of Fetal Hematopoiesis by Ribosomal Subunits RPS19 and RPL5

ABSTRACT: Ribosomopathies are associated with anemia; yet, the precise control of ribosomal protein (RP) stoichiometry and activity during erythroid development remains elusive. Using Diamond-Blackfan anemia (DBA) as a model, we generated novel in vivo models of RP haploinsufficiency to define the roles of small and large RP subunits in fetal hematopoiesis. Rpl5 haploinsufficiency caused prenatal lethality due to a reduction in erythroid translation. Conversely, Rps19 haploinsufficiency led to neonatal stem cell exhaustion and impaired erythroid progenitor expansion, resulting from combined translational and transcriptional defects. The stem cell factor RUNX1 is upregulated in RPS19-haploinsufficient DBA patients and its deletion partially rescued hematopoiesis in Rps19 mutant mice. Our findings reveal distinct, subunit-specific roles for RPs in fetal hematopoiesis and demonstrate that imbalanced RP stoichiometry disrupts developmental programs, providing key insights into DBA pathogenesis and patient heterogeneity while underscoring the importance of balanced RP expression in stem cell and erythroid progenitor development.

ORGANISM(S): Mus musculus

PROVIDER: GSE304205 | GEO | 2026/03/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Unconventional Control of Fetal Hematopoiesis by Ribosomal Subunits RPS19 and RPL5

Project description:Ribosomopathies are associated with anemia; yet, the precise control of ribosomal protein (RP) stoichiometry and activity during erythroid development remains elusive. Using Diamond-Blackfan anemia (DBA) as a model, we generated novel in vivo models of RP haploinsufficiency to define the roles of small and large RP subunits in fetal hematopoiesis. Rpl5 haploinsufficiency caused prenatal lethality due to a reduction in erythroid translation. Conversely, Rps19 haploinsufficiency led to neonatal stem cell exhaustion and impaired erythroid progenitor expansion, resulting from combined translational and transcriptional defects. The stem cell factor RUNX1 is upregulated in RPS19-haploinsufficient DBA patients and its deletion partially rescued hematopoiesis in Rps19 mutant mice. Our findings reveal distinct, subunit-specific roles for RPs in fetal hematopoiesis and demonstrate that imbalanced RP stoichiometry disrupts developmental programs, providing key insights into DBA pathogenesis and patient heterogeneity while underscoring the importance of balanced RP expression in stem cell and erythroid progenitor development.

2026-03-05 | GSE302344 | GEO

Mechanism of action of RPS19R62W mutation in Diamond-Blackfan Anemia (DBA)

Project description:RPS19 mutations are the most common cause of the human disorder Diamond Blackfan Anemia. The R62W mutation was hypothesized to act in a dominant negative fashion and mice expressing RPS19R62W have many of the characteristics of Diamond Blackfan Anemia. Diamond-Blackfan Anemia (DBA), is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes. Mutations in the gene encoding Ribosomal Protein S19 (RPS19) have been identified in ~25% of DBA families. Most of these mutations disrupt either the translation or stability of the RPS19 protein and are predicted to cause DBA by haploinsufficiency. However, approximately ~30% of RPS19 mutations are missense mutations that do not alter the stability of the RPS19 protein and are hypothesized to act by a dominant negative mechanism. To formally test this hypothesis, we generated a transgenic mouse model expressing an RPS19 mutation in which an Arginine residue is replaced with a Tryptophan residue at codon 62 (RPS19R62W). Constitutive expression of RPS19R62W in developing mice was lethal. Conditional expression of RPS19R62W resulted in growth retardation, a mild anemia with reduced numbers of erythroid progenitors and significant inhibition of terminal erythroid maturation, similar to DBA. RNA profiling demonstrated over 700 dysregulated genes belonging to the same pathways that are disrupted in RNA profiles of DBA patient cells. The samples compared are RNA extracted from CD71 positive erythroblasts sorted from the bone marrow of wild type mice and mice expressing a mutant RPS19 (RPS19R62W) transgene

2011-06-29 | E-GEOD-22645 | biostudies-arrayexpress

Mechanism of action of RPS19R62W mutation in Diamond-Blackfan Anemia (DBA)

2011-06-29 | GSE22645 | GEO

Analysis of the interactome of RPS19 mutants

Project description:Ribosomal protein S19 (RPS19) is a 16-kDa protein found mainly as a component of the ribosomal 40 S subunit. Its mutations are responsible for Diamond Blackfan anemia, a congenital disease characterized by defective erythroid progenitor maturation. To clarify the function of RPS19, we compare the interactome of RPS19 wilde type and their two mutant proteins: RPS19-R62W and RPS19- R101H. Mutations R62W and R101H impair RPS19 ability to associate with the ribosome. We found striking differences between the interactomes of wild type and mutant RPS19 proteins. In particular, mutations abolish interactions with proteins having splicing, translational and helicase activity, thus confirming the role of RPS19 in RNA processing/metabolism and translational control.

2014-08-11 | PXD000640 | Pride

Ribosomal deficiencies in Diamond-Blackfan anemia impair translation of transcripts essential for differentiation of murine and human erythroblasts

Project description:Diamond Blackfan Anemia (DBA) is associated with developmental defects and profound anemia. Mutations in genes encoding a ribosomal protein of the small (e.g. Rps19) or large (e.g. Rpl11) ribosomal subunit are found in over half of these patients. The mutations cause ribosomal haploinsufficiency, which reduces overall translation efficiency of cellular mRNAs. We reduced expression of *Rps19* or *Rpl11* in mouse erythroblasts and investigated mRNA polyribosome association, which revealed deregulated translation initiation of specific transcripts. Among these were *Bag1*, encoding a Hsp70 co-chaperone, and *Csde1*, encoding an RNA binding protein, both expressed at increased levels in erythroblasts. Their translation initiation is cap-independent and starts from an internal ribosomal entry site (IRES), which appeared sensitive to knock down of Rps19 or Rpl11. Mouse embryos lacking Bag1 die at embryonic day E13.5 with reduced erythroid colony forming cells in the fetal liver, and low Bag1 expression impairs erythroid differentiation in vitro. Reduced expression of Csde1 impairs proliferation and differentiation of erythroid blasts. Protein but not mRNA expression of *BAG1* and *CSDE1* was reduced in erythroblasts cultured from DBA patients. Our data suggest that impaired IRES-mediated translation of mRNAs expressed at increased levels in erythroblasts contributes to the erythroid phenotype of DBA. 3 biological replicates of erythroblasts treated with different shRNA were used for polyribosomal sucrose gradients; RNA was extracted from gradients in 2 samples - mRNA associated with polyribosomes (poly) and the rest (sub).

2011-11-14 | E-GEOD-22903 | biostudies-arrayexpress

Ribosomal deficiencies in Diamond-Blackfan anemia impair translation of transcripts essential for differentiation of murine and human erythroblasts

2011-11-14 | GSE22903 | GEO

BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK

Project description:Erythropoiesis is a crucial part in hematopoietic system, while facing disruptions from various diseases conditions. Anemia and blood shortages has become global challenges, with current finite pharmacological options like EPO or glucocorticoids having limitations, especially in genetic anemias like Diamond-Blackfan anemia (DBA), calling for novel candidates in stimulating the erythropoiesis. We designed the primary human hematopoietic stem and progenitor cells (HSPCs) chemicals screening system in erythropoiesis and unexpectedly discovered a BRAF inhibitor, effectively against BRAFV600E mutant cancers, delaying erythroid differentiation while promoting progenitors’ proliferation. Further research demonstrated its efficacy in cytokine-restricted conditions and in samples from erythroid disorder patients. Mechanistically, BRAF inhibitors paradoxically activated the RAF-MEK-ERK/MAPK pathway. Unlike oncogenic BRAFV600E impaired hematopoiesis and erythropoiesis via AP-1 hyperactivation, BRAF inhibitors minimally affected HSPCs self-renewal and differentiation. In vivo studies further exhibited BRAF inhibitors' potential to enhance human hematopoiesis and erythropoiesis in severe immunodeficient mouse models and alleviate anemia symptoms in Rpl11 haploinsufficiency DBA models and other anemia models. This discovery sheds light on the MAPK pathway's role in hematopoiesis, making BRAF inhibitors a novel clinically therapeutic choice in improving hematopoietic reconstitution and the recovery of anemias like DBA.

2024-09-09 | PXD055730 |

In vitro expansion of normal and Diamond Blackfan anemia-derived peripheral blood erythroid progenitors

Project description:The Affymetrix Human Gene 2.0 ST array was used to measure differential expression of RNA isolated from normal and Diamond Blackfan anemia (DBA) erythroid progenitors after ex vivo expansion of circulating, peripheral blood derived hematopoietic stem cells under erythroid growth conditions. The gene-level probe summaries reported in this series were computed using RMA as implemented in the Bioconductor package Oligo v1.36.1. Diamond Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by erythroid aplasia, usually without perturbation of other hematopoietic lineages. Approximately 65% of DBA patients with autosomal dominant inheritance have heterozygous mutations or deletions in ribosomal protein (RP) genes while <1% of patients with X-linked inheritance have been identified with mutations in the transcription factor, GATA1. Erythroid cells from patients with DBA have not been well characterized and the mechanisms underlying the erythroid specific effects of either RP or GATA1 associated DBA remain unclear. We have developed an in vitro culture system to expand peripheral blood CD34+ progenitor cells from patients with DBA and differentiate them into erythroid cells. Cells from patients with RP or GATA1 mutations showed decreased proliferation and delayed erythroid differentiation compared to controls. RNA transcript analyses of erythroid cells from controls and patients with RP or GATA1 mutations showed distinctive differences, with upregulation of heme biosynthesis genes prominently in RP-mediated DBA and failure to upregulate components of the translational apparatus in GATA1-mediated DBA. Our data show that dysregulation of translational function is a common feature of DBA caused by both RP and GATA1 mutations.

2017-04-04 | GSE89540 | GEO

RPS19 binding with and without Diamond-Blackfan anemia variants

Project description:We found that endogenously expressed RPS19 binds evolutionarily constrained intronic elements. By assessing overexpression of WT RPS19 and RPS19 harboring the most common Diamond-Blackfan anemia missense mutations, we confirmed that disease-relevant mutations alter RPS19 binding preferences in human cells.

2023-02-14 | GSE224998 | GEO

BRAF inhibitors promote erythropoiesis and hematopoiesis via paradoxical MAPK activation (ATAC-Seq)

2024-12-03 | GSE261117 | GEO